Iron Triangle Partners LP Purchases 44,014 Shares of Insulet Co. (NASDAQ:PODD)

Iron Triangle Partners LP boosted its position in Insulet Co. (NASDAQ:PODD) by 40.0% in the 4th quarter, Holdings Channel reports. The fund owned 154,014 shares of the medical instruments supplier’s stock after purchasing an additional 44,014 shares during the period. Insulet makes up about 4.4% of Iron Triangle Partners LP’s investment portfolio, making the stock its 9th biggest position. Iron Triangle Partners LP’s holdings in Insulet were worth $40,208,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PODD. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the fourth quarter worth approximately $36,000. Itau Unibanco Holding S.A. acquired a new position in shares of Insulet in the 4th quarter valued at $42,000. SRS Capital Advisors Inc. grew its stake in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the period. Friedenthal Financial acquired a new stake in shares of Insulet during the 4th quarter worth $57,000. Finally, Assetmark Inc. raised its position in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 246 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PODD shares. Wells Fargo & Company set a $322.00 price target on Insulet in a research report on Monday, April 28th. Barclays increased their target price on shares of Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. StockNews.com cut shares of Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Stifel Nicolaus increased their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $303.81.

Insulet Stock Performance

Insulet stock opened at $310.42 on Friday. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $312.16. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market cap of $21.84 billion, a P/E ratio of 53.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The stock has a 50 day moving average of $257.45 and a 200-day moving average of $263.70.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm’s revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.73 EPS. On average, analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.